Adding Targeted Drug to Chemo Boosts Survival in Esophageal/GEJ Cancer

(MedPage Today) -- SAN FRANCISCO -- Adding a Claudin (CLDN) inhibitor to chemotherapy significantly increased progression-free (PFS) and overall survival (OS) in locally advanced gastric/gastroesophageal junction (GEJ) cancer and CLDN 18.2 expression...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news